Andreas Koulouris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andreas Koulouris has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Allan Clark
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR4 7TJ, United Kingdom
1 shared publication- Allan Clark
Norwich Medical School, University of East Anglia, Norwich, UK
1 shared publication - Andrew Hart
University of Colorado Boulder
1 shared publication G Georgiadis
James Paget University Hospital, UK
1 shared publication- Gabriella Baio
Department of Diagnostic Imaging, IRCCS Azienda Ospedaliera Universitaria San Martino — IST – National Cancer Institute, Largo Rosanna Benzi, 10, 16100, Genoa, Italy
1 shared publication H Foroutan-Sabzevari
Norfolk and Norwich University Hospital, UK
1 shared publication
Latest Publications
- 30 August 2023
- Published by Elsevier in Pancreatology
- Vol. 23 (7) , 818-828
Opioid burden in patients with inoperable pancreatic adenocarcinoma and the development of a multivariable risk prediction model for opioid use: A retrospective cohort study
- 30 August 2023
- Published by Elsevier in Pancreatology
- Vol. 23 (7) , 818-828
Opioid burden in patients with inoperable pancreatic adenocarcinoma and the development of a multivariable risk prediction model for opioid use: A retrospective cohort study
P289 Best analgesia control in pancreatic adeno – carcinoma (the BAC-PAC study)- a prospective cohort study
Introduction The standard care for the management of abdominal pain in patients with inoperable pancreatic cancer consists of opioids. Endoscopic Ultrasound-guided Coeliac Plexus Neurolysis (EUS-CPN) may be indicated if opioids are ineffective or poorly tolerated due to serious side effects. Limited and conflicting trial data is available on the efficacy of EUS-CPN, if administered early (soon after paom onset). This study aimed to assess the feasibility, justification and establish the design considerations of a randomised trial of early EUS-CPN versus standard care. These are determined by clinical parameters including fitness for endoscopy, survival after the pain onset and the standard error for possible outcome measures. Methods This was a prospective observational study. Patients with inoperable pancreatic adenocarcinoma with an Eastern Co-operative Oncology Group (ECOG) performance status of 0-3 and expected survival of at least one month were eligible. Patients were asked to complete monthly questionnaires on their performance status, pain levels, analgesic use, quality of life (QoL) and healthcare resource use. Patient carers were also involved, completing questionnaires on their quality of life. Results Over a total period of twelve months 143 patients were screened for eligibility, of which 56 met eligibility criteria. In total, 12 (21%) patients were recruited. Medical performance status ranged between 0 and 2 for those in pain. The median survival from the first record of pain was 5.2 (IQR 2.46-5.9) months. There were no statistically significant differences in the characteristics (age, sex, cancer stage) between participants and those who declined participation. The QoL of carers was moderately impaired at all time points (EQ-5D-5L summary index scores 0.86-0.89). In total, 80% of the questionnaires were completed and returned. The median Visual Analogue Score for pain was 2.6 (0.8-5.1) and the median daily morphine dose was 36 (20-48) mg. Discussion Recruitment rates remained low throughout this study. Therefore, estimates of key outcomes were imprecise for: fitness for endoscopy at the time of the pain onset; survival time after the pain onset; time from diagnosis to first opioid prescription; and the descriptive statistics of the possible outcome measures of a future trial (pain scores, opioid doses and QoL scales). Despite these limitations, overall this study supports the justification of trial administering endoscopic analgesia. However, uncertainties remain with regards to its feasibility. In a future trial, data collection procedures should minimise burden to patients. Further observational research with sufficient sample size and follow-up is required to further inform the design and feasibility of a future trial of early EUS-CPN vs. standard care.
P289 Best analgesia control in pancreatic adeno – carcinoma (the BAC-PAC study)- a prospective cohort study
Introduction The standard care for the management of abdominal pain in patients with inoperable pancreatic cancer consists of opioids. Endoscopic Ultrasound-guided Coeliac Plexus Neurolysis (EUS-CPN) may be indicated if opioids are ineffective or poorly tolerated due to serious side effects. Limited and conflicting trial data is available on the efficacy of EUS-CPN, if administered early (soon after paom onset). This study aimed to assess the feasibility, justification and establish the design considerations of a randomised trial of early EUS-CPN versus standard care. These are determined by clinical parameters including fitness for endoscopy, survival after the pain onset and the standard error for possible outcome measures. Methods This was a prospective observational study. Patients with inoperable pancreatic adenocarcinoma with an Eastern Co-operative Oncology Group (ECOG) performance status of 0-3 and expected survival of at least one month were eligible. Patients were asked to complete monthly questionnaires on their performance status, pain levels, analgesic use, quality of life (QoL) and healthcare resource use. Patient carers were also involved, completing questionnaires on their quality of life. Results Over a total period of twelve months 143 patients were screened for eligibility, of which 56 met eligibility criteria. In total, 12 (21%) patients were recruited. Medical performance status ranged between 0 and 2 for those in pain. The median survival from the first record of pain was 5.2 (IQR 2.46-5.9) months. There were no statistically significant differences in the characteristics (age, sex, cancer stage) between participants and those who declined participation. The QoL of carers was moderately impaired at all time points (EQ-5D-5L summary index scores 0.86-0.89). In total, 80% of the questionnaires were completed and returned. The median Visual Analogue Score for pain was 2.6 (0.8-5.1) and the median daily morphine dose was 36 (20-48) mg. Discussion Recruitment rates remained low throughout this study. Therefore, estimates of key outcomes were imprecise for: fitness for endoscopy at the time of the pain onset; survival time after the pain onset; time from diagnosis to first opioid prescription; and the descriptive statistics of the possible outcome measures of a future trial (pain scores, opioid doses and QoL scales). Despite these limitations, overall this study supports the justification of trial administering endoscopic analgesia. However, uncertainties remain with regards to its feasibility. In a future trial, data collection procedures should minimise burden to patients. Further observational research with sufficient sample size and follow-up is required to further inform the design and feasibility of a future trial of early EUS-CPN vs. standard care.
- 16 April 2014
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 9 (1) , 59-61
Isolated peripheral nerve sheath tumour involving the urinary bladder neck
- 16 April 2014
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 9 (1) , 59-61
Isolated peripheral nerve sheath tumour involving the urinary bladder neck
PWE-150 “The Early Growth Response Genes Induce Apoptosis in Colon Cancer Cells”
Introduction: The Egr familly (Early Growth Respone Genes) of zinc finger transcription factors, which consists of four members; Egr-1, –2, –3 and –4, have been proved to have dynamic functions in the regulation of cell growth and the immune responses.Moreover, in a number of malignancies-which is a cell growth and immune related process- it seems that Egr1 and 2 induce apoptosis leading to the inhibition of the tumour growth. The present study was designed to answer the question whether colon cancer cells undergo apoptosis when the EGR genes are exogenously introduced and if the presence of a mutant p53 can affect this apoptotic pathway. Methods: Two cell lines deriving from human colon cancer; one p53 negative (DLD1) and another p53 positive (HCT116) were transfected with Egr-1, –2 and –3 and a fluorescent protein which was the marker of the transfection. The transfected cells were incubated for 48 hours. Flow cytometry was used to create a pure population of transfected cells and 24hours later these cells were examined in the fluoroscopic microscope and compared with the controls. Results: We found that all three Egr members can suppress tumour cell growth suggesting that the function of Egr in the control of cell growth is not associated with the function of p53. In addition to the growth arrest, the transfected cells changed morphology to round shape indicating of senescence. Conclusion: This may suggest that Egr molecules are important to control the unwanted growth in response to malignant transformation. Our results not only demonstrated an important function of Egr molecules and also indicate the therapeutic potential for the treatment of tumour. Disclosure of Interest: None Declared.
PWE-150 “The Early Growth Response Genes Induce Apoptosis in Colon Cancer Cells”
Introduction: The Egr familly (Early Growth Respone Genes) of zinc finger transcription factors, which consists of four members; Egr-1, –2, –3 and –4, have been proved to have dynamic functions in the regulation of cell growth and the immune responses.Moreover, in a number of malignancies-which is a cell growth and immune related process- it seems that Egr1 and 2 induce apoptosis leading to the inhibition of the tumour growth. The present study was designed to answer the question whether colon cancer cells undergo apoptosis when the EGR genes are exogenously introduced and if the presence of a mutant p53 can affect this apoptotic pathway. Methods: Two cell lines deriving from human colon cancer; one p53 negative (DLD1) and another p53 positive (HCT116) were transfected with Egr-1, –2 and –3 and a fluorescent protein which was the marker of the transfection. The transfected cells were incubated for 48 hours. Flow cytometry was used to create a pure population of transfected cells and 24hours later these cells were examined in the fluoroscopic microscope and compared with the controls. Results: We found that all three Egr members can suppress tumour cell growth suggesting that the function of Egr in the control of cell growth is not associated with the function of p53. In addition to the growth arrest, the transfected cells changed morphology to round shape indicating of senescence. Conclusion: This may suggest that Egr molecules are important to control the unwanted growth in response to malignant transformation. Our results not only demonstrated an important function of Egr molecules and also indicate the therapeutic potential for the treatment of tumour. Disclosure of Interest: None Declared.